Disseminated Intravascular Coagulation: ISTH Score, Management, and Component Therapy

Disseminated Intravascular Coagulation: ISTH Score, Management, and Component Therapy

Acquired consumptive coagulopathy — pathogenesis, ISTH overt DIC scoring, treatment of underlying cause, and component replacement therapy

Executive Summary

Disseminated intravascular coagulation (DIC) is an acquired syndrome of widespread intravascular activation of coagulation, leading to simultaneous microvascular thrombosis and consumption of platelets and clotting factors that produces both organ ischemia and bleeding. DIC is always secondary to an underlying disorder—sepsis (most common, 30-50%), malignancy (especially adenocarcinoma and acute promyelocytic leukemia), trauma, obstetric catastrophes (placental abruption, amniotic fluid embolism, severe preeclampsia/HELLP), severe pancreatitis, snake envenomation, and transfusion reactions. The ISTH overt DIC scoring system uses platelet count, elevated fibrin marker (D-dimer or FDP), prolonged PT, and fibrinogen to confirm overt DIC at score ≥5 with sensitivity 91% and specificity 97%. Two distinct phenotypes guide management: hemorrhagic DIC (sepsis, obstetric, trauma) features platelet consumption, factor depletion, and bleeding diathesis; thrombotic DIC (chronic malignancy, large-vessel thrombosis, purpura fulminans) features fibrin deposition with end-organ ischemia. The cornerstone of treatment is aggressive management of the underlying cause—antibiotics for sepsis, delivery for obstetric DIC, leukapheresis and ATRA for APL. Component therapy is reserved for active bleeding or planned invasive procedures: platelets if <50,000/µL with bleeding (or <20,000/µL without), fresh frozen plasma 10–15 mL/kg IV if INR >1.5 with bleeding, cryoprecipitate 1 unit per 5–10 kg IV if fibrinogen <150 mg/dL (or <200 mg/dL in obstetric DIC). Anticoagulation is reserved for thrombotic-phenotype DIC. Mortality ranges from 30-60% depending on underlying cause and severity; ISTH score ≥5 doubles mortality compared to non-overt DIC. Source control remains the most important prognostic intervention.

30–60%Mortality (varies by cause)
30–50%Sepsis-associated DIC
91%ISTH score sensitivity
≥5ISTH score = overt DIC

1. Pathophysiology and Etiology

Tissue Factor Activation Cascade

DIC is initiated by widespread exposure of tissue factor (TF) to circulating factor VII, triggering the extrinsic coagulation pathway. TF is expressed on endothelial cells, monocytes, and tumor cells in response to sepsis cytokines (TNF-α, IL-1, IL-6), endothelial injury (trauma, severe burns), or tumor cell release. Massive thrombin generation overwhelms physiologic anticoagulant systems (antithrombin, protein C/S, tissue factor pathway inhibitor), producing widespread microvascular fibrin deposition. Fibrin clots in small vessels cause organ ischemia (acute kidney injury, ARDS, hepatic dysfunction, encephalopathy) and shear red blood cells passing through partially occluded vessels (microangiopathic hemolytic anemia with schistocytes).

Concurrent consumption of platelets and clotting factors produces the bleeding phenotype: thrombocytopenia, prolonged PT and aPTT, hypofibrinogenemia, and elevated D-dimer reflecting both fibrin formation and secondary fibrinolysis. The balance between thrombosis and bleeding determines clinical phenotype: acute fulminant DIC (sepsis, trauma, obstetric) typically presents with bleeding and end-organ failure; chronic compensated DIC (malignancy, aortic aneurysm, intrauterine fetal demise) presents with thrombosis and abnormal labs without overt bleeding. Most patients have features of both simultaneously.

Underlying Causes by Frequency

CategorySpecific TriggersPhenotype
Sepsis (30–50%)Gram-negative bacteremia (E. coli, Klebsiella), gram-positive sepsis, fungal sepsis, severe COVID-19Mixed (bleeding + thrombosis); high mortality
Malignancy (20–30%)Acute promyelocytic leukemia (APL), pancreatic adenocarcinoma, prostate, lung, gastric, ovarian, breastChronic compensated; thrombotic in solid tumors; severe hemorrhagic in APL
TraumaSevere trauma with massive transfusion, traumatic brain injury, burns >30% TBSA, crush injuryHemorrhagic; trauma-induced coagulopathy (TIC) overlap
Obstetric (5–10%)Placental abruption, amniotic fluid embolism, retained dead fetus, severe preeclampsia/HELLP, postpartum hemorrhageAcute hemorrhagic; rapid onset and rapid resolution post-delivery
VascularLarge aortic aneurysm, giant hemangioma (Kasabach-Merritt), aortic dissectionChronic compensated; localized consumption
Toxic/envenomationSnake bite (especially viperids), severe acute pancreatitis, ABO-incompatible transfusion, heatstrokeAcute mixed
Acute liver failureFulminant hepatic failure with reduced antithrombin and protein C synthesisMixed; overlap with hepatic coagulopathy
DIC — Simultaneous Thrombosis + Bleeding via Cascade Activation Coagulation cascade diagram: DIC — Simultaneous Thrombosis + Bleeding via Cascade Activation DIC — Simultaneous Thrombosis + Bleeding via Cascade Activation INTRINSIC (PTT) XII → XIIa XI → XIa IX → IXa VIII + IXa complex EXTRINSIC (PT/INR) Tissue Factor VII → VIIa COMMON PATHWAY X → Xa Prothrombin → Thrombin Fibrinogen → Fibrin CLOT
DIC — Coagulation Cascade Dysregulation

2. Clinical Presentation and ISTH Diagnostic Criteria

Hemorrhagic vs Thrombotic Phenotypes

Hemorrhagic DIC (sepsis, obstetric, trauma): bleeding from venipuncture sites, IV catheter sites, surgical wounds, mucous membranes (gingival, GI, urinary tract), petechiae and purpura, hematuria. Severe cases progress to massive hemorrhage. Concurrent organ dysfunction from microthrombi causes acute kidney injury, ARDS, and encephalopathy. Schistocytes on peripheral smear, mild-moderate hemolysis.

Thrombotic DIC (chronic malignancy, aortic aneurysm, purpura fulminans): venous thromboembolism, peripheral arterial thrombosis (digital gangrene), purpura fulminans (extensive skin necrosis from microvascular thrombosis—classic in meningococcal sepsis and protein C deficiency), and end-organ ischemia without overt bleeding. Trousseau syndrome (migratory superficial thrombophlebitis) is a chronic compensated DIC variant in occult malignancy. Most patients have both phenotypic features simultaneously, with one predominating.

ISTH Overt DIC Score

Parameter0 points123
Platelet count (×10⁹/L)>10050–100<50—
Elevated fibrin marker (D-dimer, FDP, fibrin monomer)None—Moderate increaseStrong increase
Prolonged PT (seconds above upper limit)<33–6>6—
Fibrinogen (mg/dL)>100<100——
Total ScoreInterpretationAction
<5Non-overt DIC (suggestive but not diagnostic)Repeat scoring daily; treat underlying cause; consider non-overt DIC sub-score
≥5Overt DIC (compatible with consumptive coagulopathy)Aggressive treatment of underlying cause; component therapy if bleeding; daily score monitoring

ISTH Score Application Caveat

The ISTH score should only be applied in patients with an underlying disorder known to cause DIC—do not apply to patients without a clinical context (e.g., isolated thrombocytopenia in an otherwise stable patient should not be scored as DIC). Trends matter more than absolute values: rapidly worsening scores indicate progressive coagulopathy and warrant escalation. The score does not differentiate hemorrhagic vs thrombotic phenotype—clinical assessment must guide management direction.

DIC Pathophysiology Cascade From underlying trigger through tissue factor activation, thrombin generation, microvascular thrombosis, organ ischemia, and consumptive coagulopathy with secondary fibrinolysis DIC Pathogenesis Cascade Trigger: sepsis, trauma, malignancy, OB Tissue Factor exposure → Thrombin generation Microvascular Fibrin Deposition → Organ ischemia, MAHA, schistocytes Factor + Platelet Consumption → Bleeding, ↓ fibrinogen, ↑ PT/aPTT Secondary Fibrinolysis ↑↑ D-dimer, ↑ FDP Bleeding + Organ Failure ISTH score ≥5 = overt DIC
Figure 1. DIC pathogenesis cascade showing dual pathway from tissue factor activation through simultaneous microvascular fibrin deposition (thrombosis) and consumption of platelets/factors (bleeding), with secondary fibrinolysis producing markedly elevated D-dimer.
ISTH Overt DIC Score Comparison table: ISTH Overt DIC Score <5 (non-overt) ≥5 (overt DIC) Platelets Fibrinogen FDP / D-dimer Description DIC unlikely; consider alternate diagnoses Overt DIC; treat >100k = 0; 50-100k = 1; <50k = 2 >100 mg/dL = 0; <100 = 1 Normal = 0; mod elev = 2; high = 3
ISTH DIC Score

3. Differential Diagnosis: DIC vs Other Coagulopathies

FeatureDICSevere Liver DiseaseVitamin K DeficiencyTTP/HUS
Platelet count↓ (consumption)↓ (sequestration in cirrhosis)Normal↓ (thrombosis)
PT/INR↑↑↑↑ (factor VII shortest half-life)Normal
aPTT↑↑↑ (later)Normal
Fibrinogen↓ (acute) / Normal-↑ (acute phase)↓ (synthesis failure)NormalNormal
D-dimer↑↑↑ (markedly elevated)Normal-mild ↑NormalMildly ↑
Factor VIIINormal-↑ (endothelial release)↓ (synthesis failure)NormalNormal-↑
Schistocytes on smear+ to ++RareNone+++
ADAMTS13 activityNormal or mildly lowNormalNormal<10%
Treatment focusUnderlying cause + componentsUnderlying liver diseaseVitamin K + plasma if bleedingPlasma exchange

Distinguishing DIC from Liver Disease Coagulopathy

Both produce thrombocytopenia and prolonged INR/aPTT, but the most reliable discriminators are: factor VIII levels (normal/elevated in DIC due to endothelial release; reduced in liver disease due to synthesis failure), D-dimer (markedly elevated in DIC; mild in liver disease), and clinical context (acute trigger like sepsis vs chronic liver dysfunction with portal hypertension). Patients with cirrhosis and superimposed sepsis frequently have BOTH conditions, complicating both interpretation and management.

4. Treatment: Source Control and Component Therapy

Underlying Cause Management — The Critical Intervention

The most important intervention in DIC is aggressive treatment of the underlying disorder. Sepsis-associated DIC: empiric broad-spectrum antibiotics within 1 hour (sepsis bundle), source control (drainage of abscess, removal of infected hardware), hemodynamic resuscitation, vasopressors as needed. Obstetric DIC: delivery of fetus and placenta is curative for placental abruption, retained dead fetus syndrome, and preeclampsia/HELLP-associated DIC—coagulopathy resolves rapidly post-delivery. APL-associated DIC: immediate ATRA 45 mg/m²/day PO on suspicion (do not wait for cytogenetic confirmation), plus arsenic trioxide. Trauma DIC: damage control surgery, hemostatic resuscitation with balanced 1:1:1 RBC:plasma:platelets, tranexamic acid 1 g IV over 10 min then 1 g over 8 hours if within 3 hours of injury (CRASH-2). Snake envenomation: species-specific antivenom.

Component Therapy Thresholds

ComponentIndicationDoseGoal
Platelets<50,000/µL with active bleeding or before invasive procedure; <20,000/µL without bleeding (prophylactic)1 unit per 10 kg (typical adult: 1 apheresis unit ≈ 6 random units)Maintain >50,000/µL with bleeding; >100,000/µL with CNS hemorrhage or surgery
Fresh frozen plasma (FFP)INR >1.5 OR aPTT >1.5× normal WITH active bleeding or planned procedure10–15 mL/kg IV (adult: 4–6 units typical)Reduce INR <1.5; correct factor deficiencies
CryoprecipitateFibrinogen <150 mg/dL with bleeding (or <200 mg/dL in obstetric DIC)1 unit per 5–10 kg IV (adult: 10 units typical)Fibrinogen >150 mg/dL (obstetric: >200)
Fibrinogen concentrateSame as cryoprecipitate; preferred when available (lower volume, faster correction)25–50 mg/kg IV (adult: 2–4 g)Same as cryoprecipitate
4-factor PCC (Kcentra)Reserved for warfarin reversal in DIC; insufficient evidence as routine DIC therapy25–50 units/kg IV based on INRRapid factor replacement

Avoid Prophylactic Component Transfusion

Transfuse blood components ONLY in actively bleeding patients or before planned invasive procedures—do not chase abnormal labs in stable, non-bleeding DIC patients. Prophylactic component therapy in stable DIC has not been shown to reduce mortality and may worsen volume overload, transfusion reactions, and immunomodulation. The exception is prophylactic platelets <20,000/µL to prevent spontaneous CNS hemorrhage in chemotherapy-induced thrombocytopenia and high-risk DIC.

5. Anticoagulation, Adjuncts, and Special Scenarios

Anticoagulation — Phenotype-Driven

Therapeutic anticoagulation in DIC is reserved for the thrombotic phenotype: chronic compensated DIC from solid malignancy (especially Trousseau syndrome), large-vessel thrombosis (deep vein thrombosis, pulmonary embolism), purpura fulminans, and giant hemangioma (Kasabach-Merritt). Heparin (UFH or LMWH) reduces ongoing thrombin generation and may stabilize the coagulopathy. Use low-dose continuous UFH ~10 units/kg/hr infusion without a bolus, or low-dose enoxaparin 1 mg/kg SC q12h. Monitor anti-Xa levels (target 0.3-0.7) rather than aPTT in DIC because baseline aPTT is already prolonged.

Therapeutic anticoagulation is contraindicated in acute hemorrhagic DIC (sepsis, obstetric, trauma) where it worsens bleeding without proven survival benefit. Prophylactic-dose VTE prevention (LMWH enoxaparin 40 mg SC daily or UFH 5,000 units SC q8h) should generally continue in critically ill DIC patients without active bleeding because VTE risk remains elevated. Decision requires individualized risk-benefit assessment with hematology consultation.

Adjunctive and Investigational Therapies

TherapyIndicationEvidence
Tranexamic acid (TXA)Trauma DIC within 3 hours; obstetric hemorrhage (WOMAN trial)CRASH-2: mortality reduction in trauma; WOMAN: maternal mortality reduction in PPH
Antithrombin concentrateSevere sepsis-associated DIC with antithrombin <70%Limited; routine use not recommended
Recombinant thrombomodulin (Recomodulin)Sepsis-associated DIC (Japan-approved)SCARLET trial: no overall survival benefit; subgroup signals in coagulopathic patients
Activated protein C (drotrecogin alfa)Withdrawn from market (PROWESS-SHOCK negative)No longer available
Recombinant factor VIIa (NovoSeven)Refractory life-threatening hemorrhage as last resortLimited evidence; thromboembolic risk; off-label outside hemophilia

When to Refer / Hospitalize

Hematology consultation: all suspected DIC cases require hematology involvement, especially for thrombotic phenotype, refractory coagulopathy, or atypical features. ICU admission: DIC by definition is critically ill—admit to ICU for hemodynamic monitoring, source control, and component therapy. Multidisciplinary care: trauma (surgery + transfusion medicine), obstetric (OB + neonatology), oncology (heme-onc + surgical onc), infectious disease (sepsis source control). Massive transfusion protocol activation: hemorrhagic DIC with ongoing bleeding meeting massive transfusion criteria (≥10 units RBC in 24h or ≥4 units in 1 hour) requires balanced 1:1:1 component delivery.

Special Scenarios

Acute promyelocytic leukemia (APL)-DIC: ATRA 45 mg/m²/day PO divided BID immediately on morphologic suspicion; do not wait for cytogenetic confirmation. APL DIC produces severe hemorrhagic phenotype with intracranial hemorrhage being leading cause of early death. ATRA differentiation rapidly resolves coagulopathy within days. Add arsenic trioxide for low-risk APL or chemotherapy combinations for high-risk.

Obstetric DIC: placental abruption, amniotic fluid embolism, retained dead fetus syndrome, and severe preeclampsia/HELLP cause acute fulminant DIC. Delivery is the most important intervention—coagulopathy resolves within 24-48 hours. Maintain fibrinogen >200 mg/dL (higher than non-pregnant threshold). Tranexamic acid 1 g IV is recommended in postpartum hemorrhage per WOMAN trial.

Snake envenomation: viperid envenomation causes consumptive coagulopathy via venom-induced fibrinogenolysis and prothrombin activation. Species-specific antivenom is curative; component therapy is bridging. Avoid heparin.

Practice Insights: Source Control Beats Factor Replacement, Symptom-Driven Transfusion, Avoid TXA

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A falling platelet count and a rising INR are repeated every six hours while the abscess or the retained products behind them go unnamed, and DIC is fundamentally a downstream problem — the only intervention that resolves it is source control of the underlying trigger (sepsis, retained intrauterine products, malignancy, trauma, snake envenomation). In practice, factor and platelet replacement are symptomatic and consumed within hours if the source remains unaddressed. In experienced practice the patients who do worst are not those with the worst initial labs; they are those whose treatment focused on transfusing to normalize numbers while the unrecognized source (retained placenta after PPH, abdominal abscess, occult APL) continued to drive the coagulopathy. Experienced practice would rather take 30 minutes to find the trigger than 30 minutes to order more blood products that will be consumed before they help.

ISTH Score Anchors Diagnosis

in experienced hands, the ISTH (International Society on Thrombosis and Haemostasis) DIC score is the diagnostic anchor: platelet count (>100 = 0, 50-100 = 1, <50 = 2), elevated FDP/D-dimer (no rise = 0, moderate rise = 2, strong rise = 3), PT prolongation (<3 sec = 0, 3-6 sec = 1, >6 sec = 2), fibrinogen (>100 mg/dL = 0, <100 = 1). Score ≥5 with underlying condition known to cause DIC = overt DIC. Score <5 = non-overt or developing DIC, monitor closely. Add clinical context: bleeding (skin/mucosal/surgical sites/IV lines), thrombosis (peripheral cyanosis, microvascular dysfunction), or both. Note that fibrinogen is an acute-phase reactant so may be falsely normal early; trend matters more than absolute value.

Source Control Is Everything

The single most important intervention is source control — DIC will continue unabated until the trigger is addressed. Sepsis: rapid empiric broad-spectrum antibiotics + source identification + drainage of any abscess + lactate-guided resuscitation. Obstetric emergencies (amniotic fluid embolism, abruption, retained products): urgent OB intervention — uterine evacuation, possible emergency hysterectomy for severe atonic bleeding. Malignancy-driven DIC (APL, mucinous adenocarcinoma): treat the cancer; APL specifically requires ATRA + arsenic trioxide which dramatically reverses the DIC. Trauma DIC: surgical hemostasis + warming + balanced massive transfusion. Snake envenomation: appropriate antivenom. Until source is controlled, transfused components are consumed and lost.

Symptom-Driven Transfusion, Not Lab-Driven

Component therapy in DIC is symptom-driven, not lab-driven — transfuse only if patient is actively bleeding or before an invasive procedure. The triggers: Platelets <50K with bleeding or pre-procedure; <20K prophylactic in non-bleeding patient (or <10K if absolutely stable). FFP if INR >1.5 with active bleeding (15-20 mL/kg, expect 30% factor activity rise) or before procedure with INR >1.5. Cryoprecipitate if fibrinogen <100-150 mg/dL with bleeding (1 unit per 10 kg raises fibrinogen ~70 mg/dL). PCC 4-factor (Kcentra) is an alternative when rapid factor correction needed and FFP not feasible. Transfusing to normalize labs in non-bleeding DIC patients wastes blood products, exposes to TRALI/TACO risk, and can paradoxically feed the consumption cycle.

Avoid TXA in Most DIC — and Heparin Only Thrombotic Phenotype

The two most consequential pharmacologic decisions in DIC: tranexamic acid (TXA) is generally CONTRAINDICATED in DIC because antifibrinolytics worsen the microvascular thrombosis component — exceptions are specific scenarios (APL with low fibrinolysis after ATRA initiation, severe hemorrhage in trauma DIC where benefits may outweigh thrombosis risk per CRASH-2 protocol within 3 hours of injury). Heparin (typically unfractionated 5-10 U/kg/hr without bolus) is reserved for chronic compensated DIC with predominant thrombotic phenotype — classically Trousseau syndrome (cancer-associated DIC with thrombotic manifestations), purpura fulminans, or large-vessel thrombosis. Acute hemorrhagic DIC generally does NOT benefit from heparin and may worsen bleeding. Activated protein C (drotrecogin alfa) was withdrawn from market (PROWESS-SHOCK trial failure).

Illustrative Scenario

A patient in their twenties presented postpartum 6 hours after delivery with progressive vaginal bleeding, uterine atony despite uterotonics, oozing from IV sites, and petechiae. Labs: Hb 7.2, platelets 38K, fibrinogen 95 mg/dL, PT 22 sec (control 12), D-dimer markedly elevated. ISTH score: platelets 2 + D-dimer 3 + PT 2 + fibrinogen 1 = 8, overt DIC. Initial treatment focused on transfusion (platelets, FFP, cryoprecipitate) but bleeding continued. On consultation, bedside ultrasound revealed retained placental fragments — the unaddressed source. Urgent uterine curettage was performed; concurrent administration of massive transfusion protocol (1:1:1 ratio PRBC:FFP:platelets), cryoprecipitate to maintain fibrinogen >150 mg/dL, and tranexamic acid (per OB hemorrhage protocol — exception to general DIC avoidance). Within 4 hours of source control + balanced transfusion, bleeding ceased, platelets and fibrinogen began rising, and ISTH score normalized over 48 hours. Patient survived without need for hysterectomy.

Takeaway: Source control (retained products evacuation) was the intervention that resolved this DIC. Transfusion without source control would have continued indefinitely. The OB-specific TXA exception applies in postpartum hemorrhage DIC per WOMAN trial protocol. ISTH score quantified severity but the clinical action that mattered was finding and removing the trigger.

Practice Pattern Refinements vs Standard Algorithm

  1. ISTH score with clinical context, not labs alone. Platelets + D-dimer + PT + fibrinogen + underlying condition. Score ≥5 = overt DIC. Watch for fibrinogen falsely normal early (acute-phase reactant); trend matters more.
  2. Source control is the primary intervention. Sepsis abx + drainage. OB urgent evacuation. APL: ATRA + ATO. Trauma: surgical hemostasis + balanced massive transfusion. Snake: antivenom. Until source addressed, transfusion is wasted product.
  3. Symptom-driven (not lab-driven) transfusion. Plt <50K + bleeding, FFP if INR >1.5 + bleeding, cryo if fibrinogen <100-150 + bleeding. Prophylactic Plt <20K. Do NOT transfuse to normalize labs in non-bleeding patients.
  4. Avoid TXA in most DIC; heparin only thrombotic phenotype. TXA worsens microvascular thrombosis — exceptions are APL post-ATRA and trauma per CRASH-2. Heparin (UFH 5-10 U/kg/hr no bolus) for chronic compensated DIC with thrombotic phenotype (Trousseau, purpura fulminans).
DIC — Source Control + ISTH-Guided Component Therapy ISTH score components, source-control priority, symptom-driven transfusion, and pharmacologic exceptions. DIC — Source Control First, Symptom-Driven Transfusion ISTH score quantifies severity · Source control resolves it · Avoid TXA in most ISTH DIC Score (≥5 = overt DIC) Platelets: >100=0 · 50-100=1 · <50=2 D-dimer / FDP: No rise=0 · Moderate=2 · Strong=3 PT prolongation: <3s=0 · 3-6s=1 · >6s=2 Fibrinogen: >100=0 · <100=1 (trend matters) Plus underlying condition known to cause DIC Source control (PRIMARY) Common triggers + action ▸ Sepsis: empiric abx + drainage ▸ OB emergency: evacuate retained products, control PPH, consider TAH ▸ APL (acute promyelocytic): ATRA + ATO ▸ Trauma: surgical hemostasis + MTP ▸ Snake: appropriate antivenom Until source addressed: transfused factors consumed within hours Symptom-driven transfusion thresholds ▸ Platelets: <50K + bleeding (or <20K prophylactic) ▸ FFP: INR >1.5 + bleeding (15-20 mL/kg) ▸ Cryoprecipitate: fibrinogen <100-150 + bleeding Pharmacologic cautions ▸ TXA generally CONTRAINDICATED (worsens microthrombi) ▸ Heparin only thrombotic phenotype (Trousseau, purpura fulminans) ▸ TXA exception: APL post-ATRA, trauma per CRASH-2/WOMAN Special scenarios ▸ APL: ATRA + arsenic trioxide curative — DIC resolves with disease treatment ▸ Trauma massive transfusion: 1:1:1 PRBC:FFP:Plt + cryoprecipitate to fibrinogen >150 + TXA <3h ▸ OB hemorrhage (WOMAN trial): TXA 1g IV within 3h reduces death — exception to DIC TXA avoidance

6. Pearls, Pitfalls, and Clinical Wisdom

Pearl 1: DIC Is Always Secondary—Find and Treat the Cause

DIC is never primary; it is always a consequence of another disorder. The most important therapeutic action is identifying and aggressively treating the underlying trigger: source control for sepsis, delivery for obstetric DIC, ATRA for APL, surgical control for trauma. Component therapy alone without addressing the root cause does not improve outcomes. Spending energy on transfusion thresholds while missing the source is a common pitfall.

Pitfall 1: Treating Lab Values Instead of Bleeding

Prophylactically transfusing components to "normalize" abnormal coagulation labs in stable, non-bleeding DIC patients does not improve outcomes and risks volume overload, transfusion reactions, TRALI, and immunomodulation. Reserve component therapy for active bleeding or planned invasive procedures. The exception is prophylactic platelets <20,000/µL to prevent spontaneous intracranial hemorrhage.

Pearl 2: D-dimer Distinguishes DIC from Liver Coagulopathy

Both DIC and severe liver disease produce thrombocytopenia and prolonged INR/aPTT, but D-dimer is markedly elevated in DIC (often >5,000 ng/mL FEU) and only mildly elevated in liver disease. Factor VIII is normal/elevated in DIC (endothelial release) and reduced in liver disease (hepatic synthesis failure). Combined with clinical context (acute trigger vs chronic liver dysfunction), these markers reliably differentiate.

Pitfall 2: Heparin in Hemorrhagic DIC

Therapeutic heparin in acute hemorrhagic DIC (sepsis, obstetric, trauma) worsens bleeding without proven survival benefit and is contraindicated outside specific scenarios. Reserve therapeutic anticoagulation for chronic compensated DIC with thrombotic phenotype—Trousseau syndrome, large-vessel VTE, purpura fulminans, Kasabach-Merritt. Prophylactic VTE dose is acceptable in stable critically ill DIC patients without active bleeding.

Pearl 3: APL-Associated DIC Is a True Emergency

Acute promyelocytic leukemia (APL) produces severe hemorrhagic DIC; intracranial hemorrhage is the leading cause of early death (within 30 days of diagnosis). Start ATRA 45 mg/m²/day immediately upon morphologic suspicion of APL—do NOT wait for cytogenetic PML-RARα confirmation. ATRA resolves coagulopathy within days through differentiation of malignant promyelocytes. Aggressive component therapy with platelets >30k, fibrinogen >150 mg/dL, INR <1.5 reduces hemorrhagic mortality.

Pitfall 3: Single Snapshot ISTH Score Without Trend

A single ISTH score <5 does not exclude DIC if trajectory is unfavorable. Repeat scoring every 24 hours in any patient with DIC trigger and abnormal coagulation; rapidly worsening scores indicate progressive coagulopathy and demand escalation. Conversely, a falling score reassures that source control is working. The ISTH non-overt DIC sub-score adds dynamic markers (changes in platelets, PT, fibrin marker, fibrinogen) for early detection.

Frequently Asked Questions

What is the ISTH overt DIC scoring system?

The ISTH overt DIC score uses 4 routine laboratory parameters: platelet count (>100k=0, 50-100k=1, <50k=2), elevated fibrin marker (D-dimer or FDP) (no=0, moderate=2, strong=3), prolonged PT (<3s=0, 3-6s=1, >6s=2), and fibrinogen (>100=0, <100=1). Total ≥5 confirms overt DIC. Score should only be applied if an underlying disorder known to cause DIC is present. Repeat daily to track progression or improvement.

When should platelets and plasma be transfused in DIC?

Transfuse platelets if count <50,000/µL with active bleeding, planned invasive procedure, or postpartum/postoperative; <20,000/µL without bleeding. FFP 10-15 mL/kg if INR >1.5 or aPTT >1.5× normal with active bleeding. Cryoprecipitate or fibrinogen concentrate if fibrinogen <150 mg/dL with bleeding (or <200 mg/dL in obstetric DIC). Avoid prophylactic transfusion in non-bleeding stable patients—correct labs only when bleeding or before procedures.

When is anticoagulation indicated in DIC?

Therapeutic-dose anticoagulation (heparin or LMWH) is reserved for the thrombotic phenotype of DIC—predominantly chronic DIC from solid malignancy, large-vessel thrombosis, or purpura fulminans. In acute hemorrhagic DIC (sepsis, obstetric, trauma), therapeutic anticoagulation worsens bleeding. Prophylactic-dose VTE prophylaxis (LMWH or UFH) should continue in critically ill DIC patients without active bleeding. Decision requires hematology input and individualized risk-benefit assessment.

What distinguishes DIC from severe liver disease coagulopathy?

Both produce prolonged INR/aPTT, low platelets, and bleeding tendency. Distinguishing features: factor VIII levels (preserved or elevated in DIC because endothelial-derived; low in liver disease), D-dimer (markedly elevated in DIC; mildly elevated in liver disease), platelet count trajectory (rapidly falling in acute DIC; chronic stable cytopenia in cirrhosis), and underlying clinical context (sepsis/malignancy/obstetric trigger for DIC; portal hypertension/jaundice for liver disease). Both may coexist.

What is the prognosis of DIC?

DIC mortality depends on underlying cause and severity. Sepsis-associated DIC carries 40-60% mortality; trauma-associated DIC 30-50%; obstetric DIC <10% with prompt management; malignancy-associated chronic DIC has variable outcomes tied to cancer trajectory. ISTH score ≥5 doubles mortality compared to non-overt DIC. Treatment of underlying cause is the most important prognostic intervention; supportive component therapy alone without source control rarely improves outcomes.

Leave a Reply

Your email address will not be published. Required fields are marked *